In recent years, it has been suggested that the TLSs and the TIBs may regulate the efficacy of immunotherapy in several types of tumors, and may closely related to the prognosis of immunotherapy. Therefore, these possibilities open a new immunotherapy research direction. The roles of TIBs and TLSs in tumorigenesis and immunotherapy have been recognized by researchers, but the specific mechanisms of action are not fully understood.[26, 27]
In our study, the results showed that a large number of B cells in GADC tumor tissues expressed CD79A/J-chain gene, and most of these cells were IgA+ plasma cells (high expression of IGHA1 and IGA2 genes). Through GO enrichment analysis, the study also found CD79A/J-chain B cells have complement activation, B cell actication and antibacterial humoral response. These results confirmed that CD79A/J-chain B cells are involved in mucosal and humoral immunity and were mainly IgA-B cells cluster.
Next, we determined the spatial structure of single cells through CSOmap, and found that T1 and T2 samples contained more cells and different types of cellular interactions and migration ability compared with cells in T3 and T4 tissues. Moreover, we observed increased expression of receptors and ligands associated with chemokines, and these data suggests that the immune cells in T1 and T2 samples may have a stronger ability to migrate. Denton et al., confirmed that CXCL13 can recruit immune cells to generate an environment permissive for germinal center formation in the lung. [28]It supports our results that the TLSs contained in T1-2 tissues form germinal centers.
The germinal center is located in the follicular region of secondary lymphatic organs. It is a special structure formed by the aggregation of B cells in the humoral immune response, and it is also a transient and dynamic micro-anatomical structure. [29]Antigen-specific B cells gather in this particular structure, and then they expand to produce somatic high frequency mutations, antibody type changes and eventually become high affinity B cells for specific antigens.[30]
Through cluster analysis, CD79A/J-chain B cells expressed high levels of the IgA1, IgA2, and SSR4 gene. We continue to find that SSR4 plays a important role in the immune microenvironment through GEPIA and TIMER database analysis. IgA is the most abundant antibody produced in mammals. IgA produced in the gastrointestinal mucosa is secretory IgA (SIgA), which is mainly composed of dimers. [31, 32]The two monomers are linked by a J-chain protein, forming an important immune protective layer on the mucosal surface. The J-chain is a glycoprotein with a molecular weight of approximately 15 kD and is mainly synthesized by IgA or IgM plasma cells and connects two monomeric units of IgA or IgM.[33] Although J-chain can polymerize IgA and IgM, IgM mainly exists in blood, and SIgA plays an important role in mucosal immunity of the body. Based on this, it is reasonable to speculate that CD79A/J-chain B cells play a role in mucosal immunity.
The SSR4 gene encodes the translocon-associated protein δ (TRAPδ) subunit. The TRAP complex comprises four transmembrane subunits (α, β, γ and δ), which exist in the ER and are involved in protein transport across the ER membrane. Studies suggest that the TRAP complex is involved in the regulation of humoral immunity by guiding the secretion and transport of immunoglobulins.[34] It is reasonable to speculate that the immune cells with high expression of SSR4 may be related to the performance of humoral immunity in human body.
In order to obtain more information about TLSs, we continued to collect 24 cases of GADCs tumor samples with or without germinal centers. We compared the structural differences by multiple immunofluorescence and digital quantitative analysis techniques. And found that CD79A+-B cells and SSR4-immune cells existed mainly in the core of germinal center in the TLSs. Moreover, The interaction between immune cells were involved in the TLSs with germinal centers. These results also support the analysis results of CSOmap prediction model.
B cells are a type of lymphocytes, which enters the peripheral lymphoid tissue after maturation of the fetal liver and bone marrow mature.[35] Subsequently, B cells proliferate and mutate in germinal centers, differentiate into memory B cells and plasma cells, and secrete antibodies to induce humoral immunity and mediate cellular immunity. The germinal center is the site of clonal expansion and affinity maturation of B cells.[30, 36]TIBs exists in some tumor tissues and are also an important part of TLSs. At present, there is still some controversy about the role of TIBs in anti-tumor immunity. Some studies showed that some immunosuppressive TIBs subtypes promoted tumor progression; [37]Another study suggested that TIBs promotes tumor immunity and inhibits the growth of tumor cells by producing tumor-specific antibodies and presenting tumor antigens. [38]The function of TIBs and the formation of TLSs will likely affect the response to immunotherapy in GADC patients.
To understand more about the role of TIBs and TLSs in GADC, we collected 165 tissue samples from 120 patients with GADC who developed TLSs, and each case included complete clinicopathological information, treatment and prognosis information. IHC analyzed results indicated that the formation of IgA-TLSs was correlated with age, differentiation, M stage, TNM stage, chemotherapy effect, PD-L1 expression, and SSR4 expression. Moreover, the presence of IgA-TLS in GADC patients was associated with better OS period.
In this study, we provided the newly insight about TLSs in GADCs and found SSR4 higher expressed in the IgA-TLSs, which may promote a better prognosis for GADC patients. Future studies will be required to confirm that the presence of SSR4 in the core of TLS is predictive of an IgA-immune response and promotes an improved prognosis in patients with GADC.